Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:CTMX NYSE:DNA NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.03+6.6%$4.20$2.93▼$7.55$592.12M1.461.52 million shs2.99 million shsCTMXCytomX Therapeutics$3.15+3.6%$3.74$1.72▼$8.21$517.37M2.084.06 million shs3.55 million shsDNAGinkgo Bioworks$8.88-1.8%$8.39$5.37▼$17.58$590.53M1.791.25 million shs969,201 shsNRXPNRx Pharmaceuticals$3.76-3.6%$3.43$1.62▼$5.05$141.29M2.141.56 million shs797,624 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+0.53%+11.85%+14.56%+21.65%+45.23%CTMXCytomX Therapeutics+3.05%0.00%-19.15%-28.30%+31.03%DNAGinkgo Bioworks-1.77%+9.90%+7.10%+25.30%+5.65%NRXPNRx Pharmaceuticals-1.76%-4.41%+21.12%+83.10%+19.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.03+6.6%$4.20$2.93▼$7.55$592.12M1.461.52 million shs2.99 million shsCTMXCytomX Therapeutics$3.15+3.6%$3.74$1.72▼$8.21$517.37M2.084.06 million shs3.55 million shsDNAGinkgo Bioworks$8.88-1.8%$8.39$5.37▼$17.58$590.53M1.791.25 million shs969,201 shsNRXPNRx Pharmaceuticals$3.76-3.6%$3.43$1.62▼$5.05$141.29M2.141.56 million shs797,624 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+0.53%+11.85%+14.56%+21.65%+45.23%CTMXCytomX Therapeutics+3.05%0.00%-19.15%-28.30%+31.03%DNAGinkgo Bioworks-1.77%+9.90%+7.10%+25.30%+5.65%NRXPNRx Pharmaceuticals-1.76%-4.41%+21.12%+83.10%+19.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.5068.99% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10284.13% UpsideDNAGinkgo Bioworks 1.67Reduce$8.50-4.28% DownsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25917.29% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, AQST, DNA, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.004/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNAGinkgo Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M14.17N/AN/A($0.28) per share-17.96CTMXCytomX Therapeutics$76.20M7.04N/AN/A$0.58 per share5.43DNAGinkgo Bioworks$170.15M3.41N/AN/A$8.74 per share1.02NRXPNRx Pharmaceuticals$1.23M110.75N/AN/A($0.54) per share-6.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.37N/AN/AN/A-202.92%8/17/2026 (Estimated)Latest NRXP, AQST, DNA, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.20$7.53 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85CTMXCytomX TherapeuticsN/A10.3810.38DNAGinkgo BioworksN/A5.155.15NRXPNRx PharmaceuticalsN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CTMXCytomX Therapeutics67.77%DNAGinkgo Bioworks78.63%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%CTMXCytomX Therapeutics3.80%DNAGinkgo Bioworks12.69%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.45 million116.91 millionOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableNRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableNRXP, AQST, DNA, and CTMX HeadlinesRecent News About These CompaniesZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE TherapeuticsJune 23 at 11:05 AM | prnewswire.comNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the ...June 22 at 8:39 AM | markets.businessinsider.comNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of DepressionJune 22 at 7:00 AM | globenewswire.comNRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...June 18, 2026 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Upgraded by Wall Street Zen to Hold RatingJune 14, 2026 | americanbankingnews.comNRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per ShareJune 10, 2026 | insidermonkey.comNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.June 5, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ OptionJune 5, 2026 | markets.businessinsider.comNRx Pharmaceuticals Announces $20 Million Public Stock OfferingJune 4, 2026 | tipranks.comNRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS TherapeuticsJune 4, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' OptionJune 4, 2026 | globenewswire.comNRx Pharmaceuticals Plans Underwritten Public Stock OfferingJune 4, 2026 | theglobeandmail.comNRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 MillionJune 3, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockJune 3, 2026 | globenewswire.comNRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's whyJune 3, 2026 | msn.comNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockJune 2, 2026 | globenewswire.comQ2 EPS Forecast for NRx Pharmaceuticals Decreased by AnalystJune 1, 2026 | marketbeat.comNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026May 28, 2026 | globenewswire.comNRx (NRXP) Q1 2026 Earnings Call TranscriptMay 27, 2026 | fool.comNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemMay 27, 2026 | globenewswire.comHere is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026NRXP, AQST, DNA, and CTMX Company DescriptionsAquestive Therapeutics NASDAQ:AQST$5.03 +0.31 (+6.57%) Closing price 04:00 PM EasternExtended Trading$5.04 +0.01 (+0.30%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.CytomX Therapeutics NASDAQ:CTMX$3.15 +0.11 (+3.62%) Closing price 04:00 PM EasternExtended Trading$3.18 +0.03 (+0.92%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Ginkgo Bioworks NYSE:DNA$8.88 -0.16 (-1.77%) Closing price 03:58 PM EasternExtended Trading$8.82 -0.07 (-0.73%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.NRx Pharmaceuticals NASDAQ:NRXP$3.76 -0.14 (-3.59%) Closing price 04:00 PM EasternExtended Trading$3.80 +0.05 (+1.20%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
